Hong Kong-based AI drug discovery firm Insilico Medicine is collaborating with Human Life Foundation Models Inc. from the US to develop an AI model focused on human longevity. This initiative aims to create one of the first AI foundation models dedicated to longevity science, which could enhance early disease risk identification and expedite therapy discovery. The partnership comes as generative AI is increasingly integrated into pharmaceutical research workflows, emphasizing a shift in biotechnology toward proactive healthspan extension rather than just reactive disease treatment.

Insilico Medicine Cayman TopCo: Insilico Medicine Cayman TopCo is a Hong Kong-based biotechnology company that applies generative artificial intelligence to accelerate drug discovery and development. It is partnering with a US-based entity to create a dedicated AI foundation model for human longevity research focused on earlier disease risk detection and faster therapy identification.
Human Life Foundation Models Inc.: Human Life Foundation Models Inc. is a privately held US company working on AI systems tailored to longevity science. It is collaborating with Insilico Medicine Cayman TopCo on an AI foundation model intended to advance understanding of aging-related risks and support the development of new therapeutic approaches.

`json
{
“AI Integration”: “Generative AI is increasingly being used in pharmaceutical research to enhance automation and predictive modeling in drug discovery.”,
“Foundation Models”: “Specialized foundation models are becoming important tools for biological and chemical research applications in life sciences.”,
“Longevity Research”: “Biotechnology is increasingly focused on understanding the processes of aging, with an aim to extend healthspan through proactive measures.”
}
`